Literature DB >> 12468433

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.

Masao Mizuki1, Joachim Schwable, Claudia Steur, Chunaram Choudhary, Shuchi Agrawal, Bülent Sargin, Björn Steffen, Itaru Matsumura, Yuzuru Kanakura, Frank D Böhmer, Carsten Müller-Tidow, Wolfgang E Berdel, Hubert Serve.   

Abstract

The receptor tyrosine kinase Flt3 is expressed and functionally important in early myeloid progenitor cells and in the majority of acute myeloid leukemia (AML) blasts. Internal tandem duplications (ITDs) in the juxtamembrane domain of the receptor occur in 25% of AML cases. Previously, we have shown that these mutations activate the receptor and induce leukemic transformation. In this study, we performed genome-wide parallel expression analyses of 32Dcl3 cells stably transfected with either wild-type or 3 different ITD isoforms of Flt3. Comparison of microarray expression analyses revealed that 767 of 6586 genes differed in expression between FLT3-WT- and FLT3-ITD-expressing cell lines. The target genes of mutationally activated Flt3 resembled more closely those of the interleukin 3 (IL-3) receptor than those of ligand-activated Flt3. The serine-threonine kinase Pim-2 was up-regulated on the mRNA and the protein level in Flt3-ITD-expressing cells. Further experiments indicated that Pim-2 function was important for clonal growth of 32D cells. Several genes repressed by the mutations were found to be involved in myeloid gene regulation. Pu.1 and C/EBPalpha, both induced by ligand-activation of wild-type Flt3, were suppressed in their expression and function by the Flt3 mutations. In conclusion, internal tandem duplication mutations of Flt3 activate transcriptional programs that partially mimic IL-3 activity. Interestingly, other parts of the transcriptional program involve novel, IL-3-independent pathways that antagonize differentiation-inducing effects of wild-type Flt3. The identification of the transcriptional program induced by ITD mutations should ease the development of specific therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468433     DOI: 10.1182/blood-2002-06-1677

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  98 in total

Review 1.  Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia.

Authors:  Steffen Koschmieder; Frank Rosenbauer; Ulrich Steidl; Bronwyn M Owens; Daniel G Tenen
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

Review 3.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 4.  The survival kinases Akt and Pim as potential pharmacological targets.

Authors:  Ravi Amaravadi; Craig B Thompson
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

5.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  George S Laszlo; Rhonda E Ries; Chelsea J Gudgeon; Kimberly H Harrington; Todd A Alonzo; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2014-03-24

Review 6.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

7.  PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

Authors:  Xiu Feng Hu; Jie Li; Scott Vandervalk; Zeping Wang; Nancy S Magnuson; Pei Xiang Xing
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

8.  Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.

Authors:  Carolina R Batista; Michelle Lim; Anne-Sophie Laramée; Faisal Abu-Sardanah; Li S Xu; Rajon Hossain; Gillian I Bell; David A Hess; Rodney P DeKoter
Journal:  Blood Adv       Date:  2018-11-13

9.  MYC and PIM2 co-expression in mouse bone marrow cells readily establishes permanent myeloid cell lines that can induce lethal myeloid sarcoma in vivo.

Authors:  Su Hwa Jang; Hee Yong Chung
Journal:  Mol Cells       Date:  2012-07-26       Impact factor: 5.034

10.  NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

Authors:  D Gerloff; R Grundler; A A Wurm; D Bräuer-Hartmann; C Katzerke; J-U Hartmann; V Madan; C Müller-Tidow; J Duyster; D G Tenen; D Niederwieser; G Behre
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.